Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.59 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8112603 | 0.94 | HDAC4 (0.62) | HDAC4AKR1C1P2RX7APPOPRM1 | |
| SCHEMBL27730585 | 0.94 | HDAC4 (0.67) | HDAC4AKR1C1P2RX7APPKMT2A | |
| SCHEMBL18764272 | 0.92 | HDAC4 (0.65) | HDAC4AKR1C1P2RX7APPKMT2A | |
| SCHEMBL11093635 | 0.88 | HDAC4 (0.51) | HDAC4AKR1C1P2RX7APPOPRM1 | |
| SCHEMBL20250135 | 0.82 | HDAC4 (0.57) | HDAC4AKR1C1P2RX7APPOPRM1 | |
| SCHEMBL2338131 | 0.82 | HDAC4 (0.57) | HDAC4AKR1C1P2RX7OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL435507 | 0.81 | HDAC4 (0.56) | HDAC4P2RX7OPRM1OPRD1OPRK1 | |
| SCHEMBL27907593 | 0.80 | HDAC4 (0.64) | HDAC4AKR1C1P2RX7OPRM1OPRD1 | |
| SCHEMBL27851055 | 0.79 | HDAC4 (0.54) | HDAC4P2RX7APPOPRM1OPRD1 | |
| SCHEMBL15108974 | 0.79 | AKR1C1 (0.55) | HDAC4AKR1C1THRBTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-14 | — | — | US | claimed |
| EP-1870416-A1 | Sulphonamido-macrocycles as tie2 inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | claimed |
| WO-2025096660-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096654-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096653-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096657-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096658-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-105461589-A | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI AVENTIS | 2016-04-06 | — | — | CN | disclosed |
| CN-105418450-A | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS | 2016-03-23 | — | — | CN | disclosed |
| CN-102083432-B | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2016-02-17 | — | — | CN | disclosed |
| CN-103068807-A | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound | TEIJIN PHARMA LTD | 2013-04-24 | — | — | CN | disclosed |
| CN-102083432-A | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI AVENTIS | 2011-06-01 | — | — | CN | disclosed |
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-14 | — | — | US | disclosed |
| EP-1870416-A1 | Sulphonamido-macrocycles as tie2 inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | TIE1, KDR, TEK | HDAC4 4543/4885AKR1C1 962/4885P2RX7 1521/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HDAC4 1630/4885AKR1C1 38/4885P2RX7 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.